News
Article
Author(s):
Dermatology Times is recapping our top expert interviews from the month of November.
Christopher Bunick, MD, PhD, highlights rademikibart's next-generation efficacy, showing stronger IL-4Rα binding affinity in atopic dermatitis and asthma.
As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives.
Bree Vanleeuwen, PA-C, and Jim Sutton, PA-C, discussed the Skin Cancer Awareness project—a unique initiative to train cosmetologists and hairdressers to recognize suspicious skin lesions and refer clients for dermatologic evaluation.
Cheever shared with Dermatology Times her excitement for educational opportunities, networking, and presentations from experts in the specialty.
In a session at Elevate-Derm West, Cheever presented on the utilization of AI within dermatology to optimize patient communication and diversify research.
From diet recommendations to biologic advancements, Jennifer Hsiao, MD, covered essential updates for treating patients with HS.
Affordable at-home treatments, including microneedling and benzoyl peroxide, were top pearls at Chilukuri's Elevate-Derm session.
Chilukuri shared that 2 new sunscreen ingredients, physalis angulata and pycnogenol, can prevent heat-induced pigmentation, offering new options for patients.
Marghoob shares key dermoscopic features to help clinicians identify benign vs malignant lesions on various locations of the body.
Murase noted small molecule treatments, like JAK inhibitors, remain unsafe for pregnant women.
Swanson shared practical tips from her Elevate-Derm West sessions, empowering clinicians with new strategies for pediatric skin care.
At Elevate-Derm West, Murase shared promising results in treating severe itch with emerging therapies, offering hope for patients with few options.
David M. Pariser, MD, FACP, FAAD, secretary and a founding board member of the International Hyperhidrosis Society, discussed the latest in hyperhidrosis research and the organization’s commitment to helping clinicians treat the condition.
Murase identifies 4 main pregnancy dermatoses—atopic eruption, polymorphic eruption, extrahepatic cholestasis, and pemphigoid gestationis—as "baby bumps."
Murase discussed safe dermatologic treatments during lactation, especially for chronic conditions needing biologics.
Block emphasized the importance of breakout sessions geared toward varying levels of experience—beginner, intermediate, and advanced.
Zirwas presented 2 sessions at SDPA on innovative care strategies for patients with AD and other itch-related diseases.
Michael Rubio, PA-C, previews the transformative programming and career-focused initiatives at this year’s Society of Dermatology Physician Associates Fall Conference in Las Vegas.
Dermatology physician associates via DPAF conduct skin checks at the Sun Bus during the Fall Conference.
At the 2024 SDPA Fall Conference, Sara Wilchowski, DMSc, MPAS, PA-C, highlighted the challenges and rewards of transitioning to industry roles, the impact of “Insta-Tok” on patient care, and the evolving landscape of dermatology.
At the 2024 SDPA Fall Conference, Tracey Vlahovic, DPM, highlighted the need for interdisciplinary collaboration in nail disorder management, underscoring the importance of mutual learning between podiatry and dermatology.
Jane Mast, PhD, DMSc, MPAS, shares her thoughts on the award, being a Derm PA, and dermatology.
At the 2024 SDPA Fall Conference, Renata Block, MMS, PA-C, emphasized the power of membership, tailored education, interdisciplinary collaboration, and advocacy in shaping the future of dermatology to improve patient outcomes.
Zirwas spoke with Dermatology Times to share the top clinical pearls and key takeaways from his discussion on contact dermatitis.
At the SDPA Fall Conference, Miranti emphasized the importance of targeted, comprehensive acne therapies and inspired attendees to embrace pediatric dermatology as a rewarding subspecialty.
At the 2024 SDPA Fall Conference, Hilary Baldwin, MD, highlighted the superiority of branded acne therapies, the necessity of tailored regimens, and the value of structured PA education.
At the 2024 SDPA Fall Conference, Hilary Baldwin, MD, highlighted innovative strategies for managing complex rosacea cases, the importance of combination approaches, and a slowing treatment pipeline.
Christopher Bunick, MD, PhD, discusses the multifactorial nature of chronic hand eczema, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways.
The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.
Unlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
